Iovance Biotherapeutics downgraded by Citizens JMP
$IOVA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Citizens JMP downgraded Iovance Biotherapeutics from Mkt Outperform to Mkt Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/16/2025 | $2.00 | Buy → Neutral | UBS |
| 5/12/2025 | Buy → Hold | Truist | |
| 5/9/2025 | Mkt Outperform → Mkt Perform | Citizens JMP | |
| 10/24/2024 | $17.00 | Buy | UBS |
| 7/29/2024 | $19.00 → $10.00 | Overweight → Neutral | Piper Sandler |
| 11/20/2023 | $12.00 | Buy | Goldman |
| 9/18/2023 | $40.00 → $18.00 | Overweight | Barclays |
| 5/30/2023 | $11.00 → $17.00 | Equal Weight → Overweight | Wells Fargo |